"10.1371_journal.pone.0126298","plos one","2015-05-13T00:00:00Z","Sture Lindegren; Luciana N S Andrade; Tom Bäck; Camila Maria L Machado; Bruno Brasil Horta; Carlos Buchpiguel; Ana Maria Moro; Oswaldo Keith Okamoto; Lars Jacobsson; Elin Cederkrantz; Kohshin Washiyama; Emma Aneheim; Stig Palm; Holger Jensen; Maria Carolina B Tuma; Roger Chammas; Ragnar Hultborn; Per Albertsson","Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg,Gothenburg, Sweden; Recepta Biopharma, São Paulo, Brasil; Centro de Investigação Translacional em Oncologia (LIM24), Instituto do Câncer do Estado de São Paulo, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil; Laboratório de Investigação Médica Radioisótopos-LIM43, Departamento de Radiologiae Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil; Laboratório de Biofármacos em Células Animais, Instituto Butantan, São Paulo, Brasil; Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brasil; Cyclotron and PET Unit, KF-3982, Rigshospitalet, Copenhagen, Denmark; Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg Sweden","Conceived and designed the experiments: SL TB LJ EC KW EA SP HJ RH PA LA CM BH MT RC CB AM OKO. Performed the experiments: SL TB LJ EC KW EA SP HJ RH PA LA CM BH MT RC CB AM OKO. Analyzed the data: SL TB EC KW EA SP RH LJ PA LA CM BH MT RC CB AM OKO. Contributed reagents/materials/analysis tools: HJ MT. Wrote the paper: SL RH LA MT PA. Revised the manuscript critically for important intellectual content: TB LJ EC KW EA SP HJ PA RC CB LA MT. Final approval of the version to be published: SL TB LJ EC KW EA SP HJ RH PA LA CM BH MT CB AM OKO.","The authors have the following interests. During the research, Luciana N. S. Andrade, Bruno Brasil Horta, Oswaldo Keith Okamoto and Maria Carolina B. Tuma were researchers with fellowships or consultants hired by Recepta Biopharma, the producer of Rebmab200. The authors declare that Rebmab200 is protected by US Patent Application 2011/0129483 A1 and there are currently no further patents or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","05","Sture Lindegren","SL",18,TRUE,18,18,17,5,TRUE,TRUE,FALSE,0,NA,FALSE
